title: SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
abstract: BACKGROUND
  Because of the progressive nature of the disease, most patients with type 2 diabetes mellitus eventually require multiple treatments to achieve glycaemic targets. The majority of available therapies are insulin dependent, aiming to decrease insulin resistance and increase insulin secretion. Sodium glucose co-transporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents, limit renal glucose reabsorption promoting urinary excretion of glucose, thereby reducing plasma glucose.
  
  
  OBJECTIVE
  This article explores the mechanism of action and clinical data surrounding SGLT2 inhibitors, with a particular focus on dapagli-flozin.
  
  
  CONCLUSIONS
  Clinical trials have shown dapagliflozin to be effective in reducing glycosylated haemoglobin, weight and fasting plasma glucose, either as monotherapy or as add-on therapy to metformin, sulphonylurea and insulin. Other SGLT2 inhibitors are currently under investigation.
authors.affiliation: MBBCh, is Director, Seaport Diabetes, Launceston, Tasmania.
authors.forename: Gary
authors.initials: G
authors.lastname: Kilov
authors.forename: Stephen
authors.initials: S
authors.lastname: Leow
authors.forename: Merlin
authors.initials: M
authors.lastname: Thomas
mesh_terms: D001559:Benzhydryl Compounds; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005947:Glucose / Q000378:metabolism; D005960:Glucosides / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007687:Kidney Tubules, Proximal / Q000187:drug effects / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin; D005947:Glucose